INBX

Inhibrx is a clinical-stage biopharma, not an operating business — the $1.30M of FY2025 'revenue' is collaboration/grant noise against a $140M net loss, so the headline P/S of 1073x is meaningless and the entire $1.39B market cap is an option on two oncology assets, ozekibart (INBRX-109, a tetravalent DR5 agonist in Phase 1/2 for colorectal/Ewing sarcoma/chondrosarcoma) and INBRX-106 (a hexavalent OX40 agonist in NSCLC/HNSCC). The MD&A confirms the company is the post-spin remnant after Sanofi acquired the crown-jewel INBRX-101 program in May 2024 — the $1.69B FY2024 'net income' is the one-time gain from that merger, not earnings power, and is why FY2025 swings back to a $140M loss.

The balance sheet is the disqualifier. Operating cash burn was -$130M in FY2025 against just $124M of cash — roughly one year of runway — while $101M of long-term debt has driven liabilities to 17.3x equity and left stockholders' equity at a thread-bare $7.99M (down 94%) against a -$246M accumulated deficit. The Risk Factors are explicit and self-incriminating: the company has 'never generated any revenue from product sales,' expects to 'continue to incur significant losses for the foreseeable future,' and 'will need to raise substantial additional funds … and cannot guarantee this additional funding will be available on acceptable terms or at all,' with raising capital expected to 'cause dilution to our existing stockholders.' A near-term financing at this burn rate is close to a certainty, and with only 14.6M shares outstanding the dilution math is unforgiving.